SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Artiva Biotherapeutics Discontinues AlloNK Development

Artiva Biotherapeutics is halting further development of AlloNK (AB-101), including the planned Phase 3 pivotal trial.

ARTV
SquawkNews Desk 1 updates Updated Oct 27, 2026, 11:39 AM UTC

Story updates

11:39:15 AM UTC
SquawkNews
BRIEF-Artiva Biotherapeutics Announces Strategic Update And Discontinues Development Of AlloNK Oct 2

Related stories

Siniora Food Industries Reports Q3 Profit of 3.5 Million Dinars M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC Barksdale Resources Raises CA$15.7 Million in Private Placement Barksdale Resources closed the final tranche of its private placement, raising CA$15.7 million. M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC Reliance Power Shares Gain 9.22%, Remain Down 59% in a Year Reliance Power shares ended Thursday up 9.22%, while remaining 59% below their year-ago level. M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC Noel Tata to Retire as Trent Chairman; Bahram Vakil to Succeed Trent said Noel Tata will retire as chairman and director after business hours on November 11, 2026. The board appointed Bahram Vakil as chairman, effective November. L impact | EQUITY | Oct 29, 2026, 02:53 PM UTC Huntington Ingalls Industries Reports Quarterly Results Huntington Ingalls Industries reported results for the quarter ended September 30; no figures were provided. M impact | EQUITY | Oct 29, 2026, 02:53 PM UTC Bioextrax Raises SEK 10 Million in Rights and Directed Issues Bioextrax said it raised SEK 10 million before issue costs through rights and directed issues. M impact | EQUITY | Oct 29, 2026, 02:53 PM UTC